<?xml version="1.0"?>
<Articles JournalTitle="The Research in Heart Yield and Translational Medicine (RHYTHM)">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Erratum  Abstract</title>
    <FirstPage>2096</FirstPage>
    <LastPage>2096</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Erratum</FirstName>
        <LastName>JTHC</LastName>
        <affiliation locale="en_US">-</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>18</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">No Abstract No Abstract No Abstract</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/2096</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Vasovagal Syncope: A Review of Current and Emerging Therapies for a Common Cardiology Condition</title>
    <FirstPage>1</FirstPage>
    <LastPage>5</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Masih</FirstName>
        <LastName>Tajdini</LastName>
        <affiliation locale="en_US">1-Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.         2-Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, USA.</affiliation>
      </Author>
      <Author>
        <FirstName>Amir Hossein</FirstName>
        <LastName>Behnoush</LastName>
        <affiliation locale="en_US">Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Amirmohammad</FirstName>
        <LastName>Khalaji</LastName>
        <affiliation locale="en_US">Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Satish</FirstName>
        <LastName>Raj</LastName>
        <affiliation locale="en_US">Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>06</Month>
        <Day>20</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>02</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Vasovagal syncope (VVS), characterized by transient loss of consciousness, is among the most prevalent reasons for emergency visits worldwide. Although benign in nature, VVS can be accompanied by traumatic injury, leading to morbidity and decreased quality of life, especially in those with VVS recurrence. The management includes non-pharmacologic and pharmacologic therapies (if resistant), patient education and reassurance, salt and fluid intake increase, and physical counter-pressure maneuvers. Among medications, midodrine has shown promising results in reducing VVS recurrence and positive head-up tilt tests. Fluoxetine and atomoxetine also might be suitable candidates for VVS therapy. Permanent pacemakers, such as closed-loop stimulation, are under research and can be effective in cases unresponsive to medical treatment. In summary, while data are scarce regarding the definite treatment of VVS, there is a need for further research with novel, easy-to-use and cost-effective therapeutic methods to enhance quality of life and prevent traumatic injury.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1875</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Role of Leukemia Inhibitory Factor in Cardiovascular Disease: Signaling in Inflammation, Coagulation, and Angiogenesis</title>
    <FirstPage>6</FirstPage>
    <LastPage>13</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hadi</FirstName>
        <LastName>Rezaeeyan</LastName>
        <affiliation locale="en_US">Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Bahareh</FirstName>
        <LastName>Moghimian-Boroujeni</LastName>
        <affiliation locale="en_US">Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mehrnaz</FirstName>
        <LastName>Abdolalian</LastName>
        <affiliation locale="en_US">1-Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran.    2-Ramsar Campus, Mazandaran University of Medical Sciences, Sari, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammadreza</FirstName>
        <LastName>Javan</LastName>
        <affiliation locale="en_US">Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>05</Month>
        <Day>19</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>05</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Cardiovascular disease (CVD) is one of the principal causes of mortality in the world. Various factors have been identified in the pathogenesis of CVD. Leukemia inhibitory factor (LIF) as a secretory cytokine is one of these factors. The LIF receptor is located on endothelial cells and plays a role in the expression of specific genes in these cells. Endothelial cells are the innermost cells of blood vessels, and defects in these cells cause endothelial dysfunction and eventually CVD.
Methods: The present study is based on PubMed database information (1982&#x2013;2022) using the following words: &#x201C;cardiovascular disease,&#x201D; &#x201C;endothelial cells,&#x201D; &#x201C;leukemia inhibitory factor,&#x201D; and &#x201C;angiogenesis.&#x201D;
Results: LIF can cause arteriosclerotic plaques by activating inflammatory mechanisms in monocytes through the induction of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression. LIF can also induce vascular endothelial growth factor expression by activating signaling pathways, eventually leading to angiogenesis. Additionally, it can activate the coagulation cascade by factor VII production promotion within endothelial cells.
Conclusion Understanding the interplay between LIF and the inflammation pathways, coagulation, and angiogenesis as key factors in CVD occurrence raises the possibility of targeting this factor as a potential strategy to mitigate CVD risk.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1858</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Knowledge and Performance of Iranian Internists Regarding Dyslipidemia According to Lipid Guidelines and their Relationships with Personal and Occupational Characteristics</title>
    <FirstPage>14</FirstPage>
    <LastPage>24</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Faezeh Sadat</FirstName>
        <LastName>Naji</LastName>
        <affiliation locale="en_US">Department of Endocrinology, Vali-Asr Hospital, Endocrinology and Metabolism Research Center, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mehrzad</FirstName>
        <LastName>Mirshekari</LastName>
        <affiliation locale="en_US">Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Soha</FirstName>
        <LastName>Namazi</LastName>
        <affiliation locale="en_US">1- Clinical Pharmacy Department, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.     2- Research Center for Rational Use of Drugs, Tehran University of Medical Science, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Hesam Aldin</FirstName>
        <LastName>Varpaei</LastName>
        <affiliation locale="en_US">College of Nursing, Michigan State University, East Lansing, MI, USA.</affiliation>
      </Author>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Esteghamati</LastName>
        <affiliation locale="en_US">Department of Endocrinology, Vali-Asr Hospital, Endocrinology and Metabolism Research Center, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mahboobeh</FirstName>
        <LastName>Hemmatabadi</LastName>
        <affiliation locale="en_US">Department of Endocrinology, Vali-Asr Hospital, Endocrinology and Metabolism Research Center, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Nooshin</FirstName>
        <LastName>Shirzad</LastName>
        <affiliation locale="en_US">1- Department of Endocrinology, Vali-Asr Hospital, Endocrinology and Metabolism Research Center, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran.   2- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>12</Month>
        <Day>25</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Lipid metabolism disorders are among the most common metabolic diseases that are increasing globally and are associated with chronic metabolic disturbances. The present study aimed to determine the knowledge and practice of internal medicine physicians concerning lipid disorders according to the AHA, AACE, ESC-EAS, and NCEP-ATP-III guidelines.
Methods: This descriptive-analytical cross-sectional study selected a convenience sample of 220 internal medicine specialists from January through September 2021 in Tehran and some other Iranian cities. A 25-item researcher-designed questionnaire was used. Suggested scenarios were designed by emphasizing the points of difference in the guidelines. Content validity was approved by 10 tenured faculty members, and reliability was tested with the test-retest method.
Results: Women comprised 60% of the population. In addition, 3.2% (n=7) of the physicians had poor knowledge, 95.0% (n=209) had moderate knowledge, and 1.8% (n=4) had good knowledge of lipid disorders based on international guidelines. Moreover, performance regarding lipid disorders was poor in 25 (11.4%), moderate in 164 (74.5%), and good in 31 (14.1%) physicians. The knowledge score decreased, whereas the practice score increased with age. The knowledge score of female physicians was significantly higher than that of their male counterparts. The knowledge score was negatively correlated with the physician&#x2019;s years of experience.
Conclusion: The knowledge and performance of internists regarding dyslipidemia were rated moderate according to the AHA, AACE, ESC-EAS and NCEP-ATP III guidelines.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1784</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">In-Hospital and Midterm Outcomes of Lead Extraction: A Single-Center Clinical Study</title>
    <FirstPage>25</FirstPage>
    <LastPage>30</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Fahimeh</FirstName>
        <LastName>Valizadeh-shiran</LastName>
        <affiliation locale="en_US">1-Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.         2-Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Negin Sadat</FirstName>
        <LastName>Hosseini Mohammadi</LastName>
        <affiliation locale="en_US">1-Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.          2-Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Kiarash</FirstName>
        <LastName>Tavakoli</LastName>
        <affiliation locale="en_US">1-Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.       2-Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Arash</FirstName>
        <LastName>Jalali</LastName>
        <affiliation locale="en_US">1-Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.      2-Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Seyed Hossein</FirstName>
        <LastName>Ahmadi Tafti</LastName>
        <affiliation locale="en_US">Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Ahmad</FirstName>
        <LastName>Yaminisharif</LastName>
        <affiliation locale="en_US">Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>08</Month>
        <Day>17</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: The rate of lead extraction has steadily increased alongside the extensive use of cardiovascular implantable electronic devices. Data on the complications and safety of this challenging procedure are limited. We investigated in-hospital and midterm outcomes following lead extraction.
Methods: Data were retrieved from 51 patients who underwent pacemaker/defibrillator lead extraction procedures at Tehran Heart Center between 2016 and 2021. The procedural success rate, patients&#x2019; demographic characteristics, and in-hospital and midterm procedure-related complications were investigated.
Results: Fifty-one patients were enrolled, including 44 men (86.3%). A total of 109 leads were extracted, with a 90.2% complete procedural success rate. In-hospital death occurred in 4 patients (7.8%): 1 patient (1.9%) died from pneumonia, 1 (1.9%) from septic shock, and 2 (3.9%) from septic shock besides heparin&#x2010;induced thrombocytopenia. Adverse events in 3 patients (5.8%) were directly related to the procedure: 1 patient (1.9%) suffered lung laceration and hemorrhage, 1 (1.9%) sustained subclavian injury, and 1 (1.9%) developed tamponade. Neither reinfection nor rehospitalization was observed during follow-up.
Conclusion: Lead extraction can be considered a highly successful procedure with a low rate of death-related events and complications.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1916</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Effects of Mobile Health on Self-Care in Senior Patients with Myocardial Infarction</title>
    <FirstPage>31</FirstPage>
    <LastPage>37</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Keramat Kar</LastName>
        <affiliation locale="en_US">1-Social Determinants of Health Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.           2-Faculty of Nursing and Midwifery, Qazvin University of Medical Sciences, Qazvin, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Arash</FirstName>
        <LastName>Ghiasvand Mohammad Kani</LastName>
        <affiliation locale="en_US">Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Ahad</FirstName>
        <LastName>Alizadeh</LastName>
        <affiliation locale="en_US">Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Majid</FirstName>
        <LastName>Hajikarimi</LastName>
        <affiliation locale="en_US">Clinical Research Development Unit, Qazvin University of Medical Sciences, Qazvin, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>11</Month>
        <Day>10</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>06</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Myocardial infarction is one of the leading causes of death in the world and accounts for 23% of mortalities. Self-care for senior patients with myocardial infarction can reduce complications, multiple hospitalizations, and financial costs.
Methods: This clinical trial was performed on 128 older adults with myocardial infarction. Available sampling was done via block random sampling among patients at the Heart Clinic of Booali Hospital, Qazvin, Iran. Data were collected through interviews and demographic and self-care questionnaires regarding heart disease. Data analysis was conducted using R software, version 4.1.0, and via the mixed-effects model method and post hoc and contrast tests.
Results: The mean age of the study population was 65.54&#xB1;4.50 years. Before the intervention, self-care maintenance was not significantly different between the 2 groups. After the intervention, a statistically significant difference was observed between the groups (P=0.001). No statistically meaningful difference concerning self-care monitoring existed between the 2 groups at the beginning of the study (P=0.03); however, a significant difference emerged after the intervention (P=0.001). A difference existed between the groups regarding self-care confidence study commencement in that the self-care confidence level in the control group was higher (P=0.013), but no difference was observed following the intervention. Nonetheless, after 1 month, the groups were significantly statistically different (P=0.003) in that the self-care confidence level in the intervention group increased.
Conclusion: Mobile health could improve self-care in older adults with myocardial infarction.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1754</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Relationships between Dairy Consumption Patterns and Hypertension, Overweight, and Obesity Status</title>
    <FirstPage>38</FirstPage>
    <LastPage>46</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Ahmadreza</FirstName>
        <LastName>Rasouli</LastName>
        <affiliation locale="en_US">1 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Hamid</FirstName>
        <LastName>Khederlou</LastName>
        <affiliation locale="en_US">Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Narges</FirstName>
        <LastName>Milkarizi</LastName>
        <affiliation locale="en_US">Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Shahram</FirstName>
        <LastName>Arsang-Jang</LastName>
        <affiliation locale="en_US">Department of Biostatistics and Epidemiology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Houshang</FirstName>
        <LastName>Bavandpour Karvane</LastName>
        <affiliation locale="en_US">Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Zahra</FirstName>
        <LastName>Akbarzade</LastName>
        <affiliation locale="en_US">Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Pouria</FirstName>
        <LastName>Tavakkolian</LastName>
        <affiliation locale="en_US">3Student Research Centre, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Loghman</FirstName>
        <LastName>Sharifi</LastName>
        <affiliation locale="en_US">Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetic, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>01</Month>
        <Day>21</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>05</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Obesity is considered a widespread concern internationally. Few studies have investigated the relationships between dairy consumption and hypertension and obesity. Therefore, this study examined the above concern in students.
Method: This cross-sectional study was conducted on 292 male students (18&#x2013;30 y) living in the dormitories of Tabriz University of Medical Sciences. Students were selected via the multistage stratified random sampling method. Demographic information, anthropometric measurements, blood pressure (BP) readings, and a semi-quantitative validated questionnaire assessing dairy consumption (including a 24-hour dietary record covering 2 typical days and a holiday) were collected. After all the questionnaires were reviewed, they were coded and analyzed with Nutritionist IV software.
Results: The average age of the subjects was 22.36 years. The mean&#xB1;SD values of body mass index (BMI), waist circumference, waist-to-hip ratio, and waist circumference-to-standing height ratio were 22.68&#xB1;2.58 kg/m&#xB2;, 80.95&#xB1;7.81 cm, 0.85&#xB1;0.04, and 0.46&#xB1;0.04 among the studied population, respectively. The mean&#xB1;SD values of systolic and diastolic blood pressure were 111.84&#xB1;10 mm Hg and 70.99&#xB1;8 mm Hg, respectively. Milk consumption was associated with a low waist circumference (95% credible interval, 1.005 to 4.580; P=0.046). The odds of hypertension (defined as BP&gt;120/90 mm Hg) were 2.686 times higher in the overweight and obese group than in the normal BMI group. The risk of hypertension was 1.045 times higher for individuals with abdominal obesity than for those who did not consume dairy products.
Conclusion: Milk consumption was associated with a low waist circumference. The correlations between systolic blood pressure and anthropometric factors were statistically significant. BMI, waist circumference, and waist-to-hip ratio were positively associated with systolic blood pressure.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1799</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Efficacy of Oral Acetazolamide as Add-on Diuretic Therapy in Decongestion in Patients with Heart Failure: A Study Protocol for a Randomized Controlled Trial</title>
    <FirstPage>47</FirstPage>
    <LastPage>53</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Houshang</FirstName>
        <LastName>Bavandpour Karvane</LastName>
        <affiliation locale="en_US">Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Haleh</FirstName>
        <LastName>Ashraf</LastName>
        <affiliation locale="en_US">Department of Heart Failure, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Aghakouchakzadeh</LastName>
        <affiliation locale="en_US">Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Navid</LastName>
        <affiliation locale="en_US">Department of Heart Failure, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Bozorgi</LastName>
        <affiliation locale="en_US">Department of Cardiac Electrophysiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>02</Month>
        <Day>20</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>03</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Acute heart failure is a common clinical syndrome leading to hospital admission, with few evidence-based therapies for managing congestion. This trial aims to assess the efficacy of acetazolamide combined with loop diuretics in achieving decongestion among patients who fail to respond to oral diuretics and progress to acute decompensated heart failure in the absence of injectable furosemide.
Methods: This single-center, double-blind randomized controlled trial with a 1:1 allocation ratio aims to evaluate 130 patients admitted to the infusion ward. Participants will receive standard furosemide treatment and be randomized to either oral acetazolamide (250 mg twice daily) or placebo for 3 consecutive days. The primary objective is to assess the efficacy of combined oral acetazolamide and furosemide therapy in achieving decongestion. The prespecified secondary outcomes include the following: N-terminal pro-B-type natriuretic peptide levels on day 30, readmission rates within 3 months, health-related quality of life as assessed by the Heart Failure Quality of Life Questionnaire at 3 months, and changes in weight, creatinine levels, urinary sodium excretion, potassium levels, and hematological indices from the complete blood count on day 3 of the trial.
Conclusion: Diuretic resistance commonly occurs in patients with heart failure, underscoring the urgent need for innovative interventions that can effectively address the limitations of current diuretics, including diuretic resistance and electrolyte imbalances, while enhancing their efficacy in this patient population.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1813</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Long-Term Outcomes of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention of Moderate Lesions in Patients with Chronic Coronary Syndrome</title>
    <FirstPage>54</FirstPage>
    <LastPage>59</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Hamid</FirstName>
        <LastName>Khederlou</LastName>
        <affiliation locale="en_US">Department of Cardiology, Zanjan University of Medical Sciences, Zanjan, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mehrdad</FirstName>
        <LastName>Mohajeri</LastName>
        <affiliation locale="en_US">Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Houshang</FirstName>
        <LastName>Bavandpour Karvane</LastName>
        <affiliation locale="en_US">Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Arash</FirstName>
        <LastName>Jalali</LastName>
        <affiliation locale="en_US">Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mojtaba</FirstName>
        <LastName>Salarifar</LastName>
        <affiliation locale="en_US">Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>07</Month>
        <Day>28</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>05</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Fractional flow reserve (FFR) is crucial to evaluating coronary artery stenosis in patients diagnosed with chronic coronary syndrome (CCS). By assessing the severity of stenosis, FFR assists in determining whether percutaneous coronary intervention (PCI) is necessary.
Methods: Conducted at Tehran Heart Center from 2013 through 2017, this cohort study involved 52,248 CCS patients who underwent coronary angiography. Among them, 598 symptomatic individuals, despite receiving comprehensive medical treatment, underwent FFR assessment. Subsequently, 225 patients with positive FFR (&#x2264;0.80) underwent PCI, while 373 patients received solely medical treatment. The patients were monitored for 3 years to evaluate primary and secondary endpoints.
Results: After 3 years, the PCI group demonstrated a lower incidence of the primary composite endpoint, consisting of all-cause mortality, nonfatal myocardial infarction, repeat target vessel/lesion revascularization (TVR/TLR), and coronary artery bypass graft surgery, than the medical treatment group (HR, 0.85; 95% CI, 0.74 to 0.98; P=0.012). Additionally, urgent TVR/TLR significantly decreased in the PCI group (HR, 0.56; 95% CI, 0.42 to 0.74; P&lt;0.001).
Conclusion: FFR-guided PCI demonstrated effectiveness in reducing long-term major adverse cardiac events, primarily by lowering the incidence of TVR/TLR. The results emphasize the significance of FFR-guided PCI in addressing stenosis rather than alleviating ischemia.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1898</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">A Case of Antenatal Diagnosis of Absent Pulmonary Valve Syndrome with Intact Ventricular Septum, Large Patent Ductus Arteriosus, and Ascending Aorta Dilatation</title>
    <FirstPage>60</FirstPage>
    <LastPage>65</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Fariba</FirstName>
        <LastName>Ghader</LastName>
        <affiliation locale="en_US">Department of Pediatric Cardiology, Rajaie Cardiovascular Medical and Research Institute, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammadreza</FirstName>
        <LastName>Mirzaaghayan</LastName>
        <affiliation locale="en_US">Department of Cardiac Surgery, School of Medicine, Children&#x2019;s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>11</Month>
        <Day>17</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Absent pulmonary valve syndrome (APVS) is a rare congenital anomaly characterized by rudimentary PV tissue with variable degrees of PV stenosis and regurgitant pulmonary blood flow. In most cases, it is associated with tetralogy of Fallot. In a minority of APVS cases, with an unknown frequency, intact ventricular septum (IVS), patent ductus arteriosus, and possible tricuspid atresia are present. This condition is known as non-Fallot type APVS.
We describe a case of an antenatal diagnosis of APVS with IVS, a large patent ductus arteriosus, and ascending aorta dilatation. The mother was referred to our center at 32 weeks of gestation due to cardiomegaly on sonography. Fetal echocardiography revealed cardiomegaly, right atrial and ventricular enlargement, aneurysmal dilatation of the main pulmonary artery, and mild dilatation of the pulmonary artery branches. Also observed were IVS, rudimentary PV tissue with severe to-and-fro turbulence across the PV, a widely open ductus arteriosus, ascending aorta dilatation, and levorotation of the heart.
After childbirth, our diagnosis was confirmed by echocardiography and surgery. The baby experienced severe respiratory distress. At 15 days of life, surgical intervention in the form of pulmonary artery arterioplasty was performed, resulting in good outcomes. The patient underwent follow-up for 6 months and showed reasonable health.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1961</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Percutaneous Balloon Pericardiotomy and Window Creation for Treating Recurrent Massive Pericardial Effusion in Patients with Cancer: A Case Series and Literature Review</title>
    <FirstPage>66</FirstPage>
    <LastPage>69</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Azin</FirstName>
        <LastName>Alizadehasl</LastName>
        <affiliation locale="en_US">Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Ata</FirstName>
        <LastName>Firouzi</LastName>
        <affiliation locale="en_US">Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Haniye</FirstName>
        <LastName>Hajiali Fini</LastName>
        <affiliation locale="en_US">Adult Echocardiography Department, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Parisa</FirstName>
        <LastName>Firoozbakhsh</LastName>
        <affiliation locale="en_US">Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Negar</FirstName>
        <LastName>Dokhani</LastName>
        <affiliation locale="en_US">Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Rezvaneh</FirstName>
        <LastName>Shourmeij</LastName>
        <affiliation locale="en_US">Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>04</Month>
        <Day>05</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>12</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Cancer is the second leading cause of death worldwide, and pericardial effusion is relatively common in these patients. What constitutes the best therapeutic method for treating pericardial effusion in patients with cancer is controversial. Recent decades have witnessed the introduction of percutaneous balloon pericardiotomy, an effective and less-invasive method with lower recurrence rates than pericardiocentesis for draining pericardial effusion in patients with cancer who have a poor prognosis.
We herein describe 2 patients with a history of metastatic melanoma and metastatic breast cancer, presenting with symptomatic massive pericardial effusions. The patients had experienced 2 episodes of cardiac tamponade in the preceding 4 to 5 months, treated via surgical drainage. In their current episode, they were both successfully treated via percutaneous balloon pericardiotomy, and there was no recurrence of significant pericardial effusion reported during the follow-up.</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1827</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Impella CP-Assisted Balloon Aortic Valvuloplasty in 2 High-Risk Patients</title>
    <FirstPage>70</FirstPage>
    <LastPage>73</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Mohsen</FirstName>
        <LastName>Mohandes</LastName>
        <affiliation locale="en_US">Interventional Cardiology Unit, Cardiology Division, Joan XXIII University Hospital, Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.</affiliation>
      </Author>
      <Author>
        <FirstName>M&#xF3;nica</FirstName>
        <LastName>Fuertes</LastName>
        <affiliation locale="en_US">Interventional Cardiology Unit, Cardiology Division, Joan XXIII University Hospital, Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.</affiliation>
      </Author>
      <Author>
        <FirstName>Alberto</FirstName>
        <LastName>Pernigotti</LastName>
        <affiliation locale="en_US">Interventional Cardiology Unit, Cardiology Division, Joan XXIII University Hospital, Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.</affiliation>
      </Author>
      <Author>
        <FirstName>Diego</FirstName>
        <LastName>Zambrano</LastName>
        <affiliation locale="en_US">Interventional Cardiology Unit, Cardiology Division, Joan XXIII University Hospital, Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>12</Month>
        <Day>11</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Balloon aortic valvuloplasty (BAV) is a therapeutic option as palliative or bridging therapy in severe aortic stenosis, even though it is a risky procedure, especially in patients with concomitant left ventricular dysfunction. The use of percutaneous ventricular assist devices, such as the Impella CP, in this scenario provides optimal circulatory support and considerably reduces the risk of the procedure. Two patients with severe aortic stenosis and left ventricular dysfunction underwent BAV with the support of the Impella-CP. The Impella CP provided adequate support in both high-risk patients and safely allowed BAV. &#xA0;</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1771</web_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>The Research in Heart Yield and Translational Medicine (RHYTHM)</JournalTitle>
      <Issn>3115-7270</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Concerns Regarding the Potential Drug Side Effects and Follow-Up Duration in the Study &#x201C;Comparison of the Efficacy of Atorvastatin and Rosuvastatin in Preventing Atrial Fibrillation after Coronary Artery Bypass Grafting&#x201D;</title>
    <FirstPage>74</FirstPage>
    <LastPage>75</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Fateme</FirstName>
        <LastName>Omidi</LastName>
        <affiliation locale="en_US">Department of Cardiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Elnaz</FirstName>
        <LastName>Javanshir</LastName>
        <affiliation locale="en_US">Tabriz University of Medical Sciences, Cardiovascular Research Center, Madani Heart Center, Tabriz, Iran.</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>11</Month>
        <Day>19</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>07</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">No Abstract No Abstract No Abstract</abstract>
    <web_url>https://jthc.tums.ac.ir/index.php/jthc/article/view/1962</web_url>
  </Article>
</Articles>
